New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Coronary Syndromes Managed With PCI
This medical News / Journal title : :New Updates To AHA/ACC/SCAI Clinical Guidelines Recommend Treatment With Effient(R) For Patients With Acute Coronary Syndromes Managed With PCI
Effient(R) (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.
Read Full about this medical News / resources
- Results From A Global Registry Of Acute Coronary Events Study
- TCA Cellular Presents Promising Adult Stem Cells Treatment In Heart Attack Victims At SCAI Conference
- First Patient Enrolled In CYPRESS, A Dual Antiplatelet Therapy Trial With The CYPHER(R) Sirolimus-Eluting Coronary Stent
- Get With The Guidelines Hospitals Improving Care, Eliminating Disparities
- HIV â Aids Advocacy and Clinical Work | Acute HIV Infection
- New Insights Into Treatment Options For Patients Suffering From Severe Alcoholic Hepatitis
- Juventas Therapeutics Enrolling Phase I Clinical Trial Of JVS-100 For Patients With Heart Failure
- Clinical Paradox: Why “Thick” Blood Protects From A Heart Attack
- Sunesis Announces Data From Phase 2 Clinical Program Of Voreloxin In Acute Myeloid Leukemia Support Phase 3 Trial In Relapsed Or Refractory Patients
- Patients Without Health Insurance, Or Those With Financial Concerns, More Likely To Delay Seeking Care For Heart Attack
- Money Worries Delay Heart Attack Treatment - Health News - Health.com
- Treatment Of Anemia With Erythropoietin May Benefit Heart Failure Patients
- Chronic Pelvic Pain Syndromes: Clinical, Urodynamic, And Urothelial Observations
- Clinical Trial Test Helps Measure Effectiveness Of Treatment For Patients With Metastatic Cancer
- New Tool To Rule Out Coronary Heart Disease In Primary Care